Back
Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs)
Journal article

Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs)

  • Scherber, Robyn M. Hematology and Oncology, Oregon Health and Sciences University, Portland, OR
  • Geyer, Holly Mayo Clinic, Scottsdale, AZ
  • Harrison, Claire N. Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
  • Kosiorek, Heidi E. Mayo Clinic, Scottsdale, AZ
  • Dueck, Amylou C. Mayo Clinic, Scottsdale, AZ
  • Kiladjian, Jean-Jacques Hôpital Saint-Louis et Université Paris Diderot, Paris, France
  • Slot, Stefanie Hematology Department, VU University Medical Center, Amsterdam, Netherlands
  • Xiao, Zhijian Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
  • Zweegman, Sonja Department of Hematology, VUMC, Amsterdam, Netherlands
  • Sackmann, Federico Fundaleu, Buenos Aires, Argentina
  • Kerguelen Fuentes, Ana University Hospital La Paz, Madrid, Spain
  • Hernandez-Maraver, Dolores La Paz University Hospital, Madrid, Spain
  • Döhner, Konstanze Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
  • Radia, Deepti Guy's & St Thomas NHS Trust, London, United Kingdom
  • Muxi, Pablo J. Hospital Britanico, Montevideo, Uruguay
  • Besses, Carlos Hematology Department, Hospital del Mar, Barcelona, Spain
  • Cervantes, Francisco Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
  • Johansson, Peter L. NU Hospital Organization, Uddavella, Sweden
  • Andreasson, Bjorn NU Hospital Organization, Uddavella, Sweden
  • Rambaldi, Alessandro Ospedali Riuniti di Bergamo, Bergamo, Italy
  • Barbui, Tiziano Hospital Papa Giovanni XXIII and Research Foundation, Bergamo, Italy
  • Bonatz, Karin Universitätsmedizin, Mannheim, Germany
  • Reiter, Andreas III. Medizinische Klinik, Medizinische Fakultät Mannheim der Uni Heidelberg, Mannheim, Germany
  • Boyer, Francoise Centre Hospitalier Universitaire, Angers, France
  • Etienne, Gabriel Fi-LMC group, Pessac, France
  • Ianotto, Jean-Christophe Centre Hospitalier Universitaire, brest, France
  • Ranta, Dana Hospitalier Universitaire, Nancy, Nancy, France
  • Roy, Jean Division of Hematology and Oncology, Maisonneuve-Rosemont Hospital, Montreal, Canada
  • Cahn, Jean-Yves Clinique Universitaire d'Hématologie, Grenoble University Hospital, Grenoble, France
  • Maldonado, Norman I School of Medicine, University of Puerto Rico, San Juan, PR
  • Barosi, Giovanni Laboratorio Epidemiologia Clinica e Registro Italiano Mielofibrosi, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
  • Ferrari, Maria Ospedali Riuniti di Bergamo, Bergamo, Italy
  • Gale, Robert Peter Celgene Corp., Summit, NJ
  • Birgegard, Gunnar Dept. of Hem., Div. of Med., Institution for Medical Sciences, Uppsala, Sweden
  • Xu, Zefeng State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
  • Zhang, Yu Biopharmaceutical R&D Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China
  • Sun, Xiujuan State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
  • Xu, Junqing Institute of Hematology and Blood Diseases Hospital, Tianjin, China
  • Zhang, Peihong Institute of Hematology and Blood Diseases Hospital, Tianjin, China
  • te Boekhorst, Peter A. Erasmus MC/Centrumlocatie, Rotterdam, Netherlands
  • Commandeur, Suzan Leiden University Medical Center, Leiden, Netherlands
  • Schouten, Harry C. Department of Internal Medicine - Hematology, Maastricht University Medical Center, Maastricht, Netherlands
  • Pahl, Heike L Department of Experimental Anaesthesiology, University Hospital Freiburg, Freiburg, Germany
  • Griesshammer, Martin Department of Hematology and Oncology, Johannes-Wesling Clinic Minden, Minden, Germany
  • Stegelmann, Frank Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
  • Lehmann, Thomas University Hospital, Basel, Switzerland
  • Vannucchi, Alessandro M. Hematology, Universita degli Studi di Firenze, Firenze, Italy
  • Passamonti, Francesco Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
  • Samuelsson, Jan Department of Internal Medicin, Section of Hematology, Stockholm South Hospital, Stockholm, Sweden
  • Mesa, Ruben A. Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ
Show more…
Published in:
  • Blood. - American Society of Hematology. - 2015, vol. 126, no. 23, p. 4073-4073
Immunology
Cell Biology
Biochemistry
Hematology
English Abstract
Background: The Philadelphia chromosome negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF) all have a time dependent risk of progression to either an advanced myelofibrotic state (post ET/PV MF) and/or to acute myeloid leukemia. The impact of disease duration upon the MPN symptom burden is not well understood, nor are the precise mechanisms of disease progression. We sought to better understand the impact of disease duration on MPN symptom burden.
Methods:
Symptom burden data was collected utilizing the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) amongst MPN patients, collected at the time of an office visit in an international cohort of MPN patients as previously described (Scherber et. al.). Symptom burden assessment was a previously validated 27-item symptom burden questionnaire scored on a 0-10 scale (0= as good as it can be, 10 = as bad as it could be). The patient or provider was asked to report the time since MPN diagnosis. MPN duration was determined to be early if the diagnosis was established between 0 to 5 years ago, intermediate if the diagnosis was established between 6 to 10 years ago, and late if the diagnosis was established 11 years ago or more. Anemia was defined as a red blood cell count less than 10 g/dL, leukopenia was defined as a white blood cell count was below 4 x 109, and thrombocytopenia if the platelet count was below 150 x109. Statistical significance was calculated using ANOVA f-test and chi squared.
Results:
Patient demographics and disease burden: A total of 1443 patients responded to the survey, including 592 (41%) ET, 549 (38%) PV, and 302 (21%) MF patients, including 181 (60%) primary MF, 67 (22%) post-ET MF, and 54 (18%) post-PV MF. Among MF patients, mean duration of MPN diagnosis was 9 years, and mean duration MF diagnosis was 4.7 years. Among respondents, 757 fit criteria for early disease duration, 353 fit criteria for intermediate disease duration, and 333 fit criteria for late disease duration. Respondent mean age was 62 years and approximately half of respondents were female (55%). Patients with longer diagnosis duration tended to be older (p=0.009) and were most likely to have anemia (0.02), leukopenia (p=0.01), or thrombocytopenia (p=0.03). These individuals were also most likely to have a history of hemorrhage (p=0.007) or require red blood cell transfusions (p<0.001).
Combined cohort symptom burden: On average among the combined cohort of ET, PV and MF patients, symptoms tended to worsen with time with this effect being significant for symptom items of fatigue (BFI, p<0.04), concentration (p=0.007), insomnia (p=0.02), sexual difficulties (p=0.002), cough (p=0.03), night sweats (p=0.002), and pruritus (p=0.02). Symptoms of early satiety (p=0.004), concentration difficulties (p=0.01), insomnia (p=0.03), sexual difficulties (p=0.02), cough (p=0.01), and night sweats (p=<0.001) had significantly higher prevalence in those with longer disease duration. Similarly, the total calculated MPN-10 score (p=0.008) and quality of life assessment (0.03) demonstrated worsened outcomes with time (Table 1). No significant differences in symptoms for the combined cohort were observed among individuals diagnosed 0 to 1 years ago compared to those with a diagnosis established between 2 and 5 years ago.
Symptom burden in MPN subtypes. When evaluating specific MPN types, patients with essential thrombocythemia experienced significantly greater sexual difficulties over time (p=0.03). The severity (p=0.01) and incidence (p=0.03) of pruritus and incidence of night sweats (p<0.001) were significantly increased over time for individuals with PV. For those with MF, the severity (p= 0.01) and incidence (p=0.009) of cough also significantly increased with longer diagnosis duration.
Discussion
Overall, significant worsening in symptom burden can be recognized over time for individuals diagnosed with MPNs. Diagnosis may not necessarily correlate with disease duration as the timing of diagnosis may be delayed from onset of disease. Given the intent of this abstract to evaluate changes with disease duration, we did not investigate correlations between symptom burden and cytopenias. We do know that risk factors for survival in the MPNs include older age and thrombosis, however, disease duration should be investigated as an alternative marker of burden in future survival studies.


Disclosures
Harrison: CTI Biopharma: Consultancy, Honoraria, Speakers Bureau; Shire: Speakers Bureau; Gilead: Honoraria; Novartis: Honoraria, Research Funding, Speakers Bureau; Sanofi: Honoraria, Speakers Bureau. Kiladjian:Incyte Corporation: Consultancy; Novartis: Other: Travel grant; Research Funding paid to institution (Hôpital Saint-Louis et Université Paris Diderot); Novartis: Consultancy. Zweegman:Celgene: Research Funding; Janssen: Research Funding; Takeda: Research Funding. Barbui:Novartis: Speakers Bureau. Etienne:Novartis: Consultancy, Honoraria, Other: Congress Travel/Accomodations, Research Funding, Speakers Bureau; BMS: Consultancy, Honoraria, Speakers Bureau; ARIAD: Consultancy, Honoraria, Speakers Bureau. te Boekhorst:CTI Biopharma: Consultancy; Novartis: Consultancy. Vannucchi:Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Other: Research Funding paid to institution (University of Florence), Research Funding; Shire: Speakers Bureau; Baxalta: Membership on an entity's Board of Directors or advisory committees. Mesa:Novartis. Research- incyte, Gilead, cti, Genentech, promedior, NS Pharma: Consultancy.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.ch/global/documents/183332
Statistics
Document views: 27 File downloads: